J Clin Neurol.  2017 Jul;13(3):281-286. 10.3988/jcn.2017.13.3.281.

Factors Associated with Favorable Outcome of Topiramate Migraine Prophylaxis in Pediatric Patients

• Yoo IH
• Kim W
• Kim H
• Lim BC
• Hwang H
• Chae JH
• Choi J
• Kim KJ

• KMID: 2391672
• DOI: http://doi.org/10.3988/jcn.2017.13.3.281

Abstract

BACKGROUND AND PURPOSE
There are few studies that have investigated predictive factors related to migraine prophylaxis of which produced inconsistent results. The aim of this study was to identify factors that can predict the treatment response to topiramate prophylaxis in pediatric patients with migraine.
METHODS
One hundred and thirteen patients who were older than 7 years and received topiramate for at least 3 months were recruited from the Seoul National University Bundang Hospital outpatient clinic from 2005 to 2014. A positive response was defined as a reduction of more than 50% in the number of migraine episodes after topiramate treatment. Proposed predictive factors such as migraine characteristics including severity and frequency were assessed, as were other data on sex, disease duration, associated symptoms, family history, and impairment of daily activities.
RESULTS
Seventy patients (61.9%) responded to prophylactic treatment with topiramate. Patients who experienced significant impairment in daily activities showed significant benefit from the treatment (p=0.004). Sex, the severity, frequency, and duration of migraine episodes, disease duration, treatment duration, age at onset, and associated symptoms were not significantly related to a response to topiramate treatment.
CONCLUSIONS
Migraine characteristics and associated symptoms were not significantly related to a response to topiramate treatment. However, patients with significant impairment in daily activities showed significant benefit from the treatment, and so prophylactic topiramate treatment should be strongly encouraged in this patient group.

Keyword

migraine; predictive factor; prophylaxis; topiramate

MeSH Terms

Age of Onset
Humans
Migraine Disorders*
Outpatient Clinics, Hospital
Seoul

Figure

• 

  Fig. 1 Diagram of patient selection.

Reference

1. Bille BS. Migraine in school children. A study of the incidence and short-term prognosis, and a clinical, psychological and electroencephalographic comparison between children with migraine and matched controls. Acta Paediatr Suppl. 1962; 136:1–151. PMID: 13869189.

2. Hershey AD. Pediatric headache: update on recent research. Headache. 2012; 52:327–332. PMID: 22288386.

3. Lewis DW. Pediatric migraine. Neurol Clin. 2009; 27:481–501. PMID: 19289227.

4. Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ. 1994; 309:765–769. PMID: 7950559.

5. Rho YI, Chung HJ, Lee KH, Eun BL, Eun SH, Nam SO, et al. Prevalence and clinical characteristics of primary headaches among school children in South Korea: a nationwide survey. Headache. 2012; 52:592–599. PMID: 21929660.

6. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache. 1993; 33:29–35. PMID: 8436495.

7. Wasiewski WW. Preventive therapy in pediatric migraine. J Child Neurol. 2001; 16:71–78. PMID: 11292228.

8. Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs. 2010; 12:269–275. PMID: 20593910.

9. Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache. 2000; 40:539–549. PMID: 10940092.

10. Kim H, Byun SH, Kim JS, Lim BC, Chae JH, Choi J, et al. Comparison of flunarizine and topiramate for the prophylaxis of pediatric migraines. Eur J Paediatr Neurol. 2013; 17:45–49. PMID: 23111149.

11. Serdaroglu G, Erhan E, Tekgul H, Oksel F, Erermis S, Uyar M, et al. Sodium valproate prophylaxis in childhood migraine. Headache. 2002; 42:819–822. PMID: 12390647.

12. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J. Topiramate Pediatric Migraine Study Investigators. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache. 2005; 45:1304–1312. PMID: 16324162.

13. Lewis D, Winner P, Saper J, Ness S, Polverejan E, Wang S, et al. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age. Pediatrics. 2009; 123:924–934. PMID: 19255022.

14. Sorge F, De Simone R, Marano E, Nolano M, Orefice G, Carrieri P. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study. Cephalalgia. 1988; 8:1–6.

15. Headache Classification Subcommittee of the International Headache Society (IHS). The International Classification of Headache Disorders, 2nd ed. Cephalalgia. 2004; 24(suppl 1):9–160. PMID: 14979299.

16. Hershey AD. Pediatric headache. Continuum (Minneap Minn). 2015; 21:1132–1145. PMID: 26252596.

17. Pringsheim T, Davenport W, Mackie G, Worthington I, Aubé M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci. 2012; 39(2 Suppl 2):S1–S59.

18. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015; 21:973–989. PMID: 26252585.

19. Lucetti C, Nuti A, Pavese N, Gambaccini G, Rossi G, Bonuccelli U. Flunarizine in migraine prophylaxis: predictive factors for a positive response. Cephalalgia. 1998; 18:349–352. PMID: 9731940.

20. Rossi P, Fiermonte G, Pierelli F. Cinnarizine in migraine prophylaxis: efficacy, tolerability and predictive factors for therapeutic responsiveness. An open-label pilot trial. Funct Neurol. 2003; 18:155–159. PMID: 14703897.

21. Wöber C, Wöber-Bingöl C, Koch G, Wessely P. Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia. 1991; 11:251–256. PMID: 1790569.

22. Lampl C, Huber G, Adl J, Luthringshausen G, Franz G, Marecek S, et al. Two different doses of amitriptyline ER in the prophylaxis of migraine: long-term results and predictive factors. Eur J Neurol. 2009; 16:943–948. PMID: 19456855.

23. Yang CP, Chang MH, Li TC, Hsieh CL, Hwang KL, Chang HH. Predicting prognostic factors in a randomized controlled trial of acupuncture versus topiramate treatment in patients with chronic migraine. Clin J Pain. 2013; 29:982–987. PMID: 23370087.

24. Amery WK, Caers LI, Aerts TJ. Flunarizine, a calcium entry blocker in migraine prophylaxis. Headache. 1985; 25:249–254. PMID: 3897128.

25. Raieli V, Pitino R, Giordano G, Spitalieri C, Consolo F, Puma D, et al. Migraine in a pediatric population: a clinical study in children younger than 7 years of age. Dev Med Child Neurol. 2015; 57:585–588. PMID: 25586426.

26. Virtanen R, Aromaa M, Rautava P, Metsähonkala L, Anttila P, Helenius H, et al. Changing headache from preschool age to puberty. A controlled study. Cephalalgia. 2007; 27:294–303. PMID: 17376106.

27. Eidlitz-Markus T, Gorali O, Haimi-Cohen Y, Zeharia A. Symptoms of migraine in the paediatric population by age group. Cephalalgia. 2008; 28:1259–1263. PMID: 18727643.

28. Bisdorff A, Andrée C, Vaillant M, Sándor PS. Headache-associated dizziness in a headache population: prevalence and impact. Cephalalgia. 2010; 30:815–820. PMID: 20647172.

29. Vuković V, Plavec D, Galinović I, Lovrencić-Huzjan A, Budisić M, Demarin V. Prevalence of vertigo, dizziness, and migrainous vertigo in patients with migraine. Headache. 2007; 47:1427–1435. PMID: 18052952.

30. Noseda R, Burstein R. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain. 2013; 154(Suppl 1):

31. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995; 35:387–396. PMID: 7672955.

32. Kelman L. The premonitory symptoms (prodrome): a tertiary care study of 893 migraineurs. Headache. 2004; 44:865–872. PMID: 15447695.

33. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001; 41:646–657. PMID: 11554952.

34. Anda R, Tietjen G, Schulman E, Felitti V, Croft J. Adverse childhood experiences and frequent headaches in adults. Headache. 2010; 50:1473–1481. PMID: 20958295.

35. Milde-Busch A, Blaschek A, Heinen F, Borggräfe I, Koerte I, Straube A, et al. Associations between stress and migraine and tension-type headache: results from a school-based study in adolescents from grammar schools in Germany. Cephalalgia. 2011; 31:774–785. PMID: 21233282.

36. Schankin CJ, Rémi J, Klaus I, Sostak P, Reinisch VM, Noachtar S, et al. Headache in juvenile myoclonic epilepsy. J Headache Pain. 2011; 12:227–233. PMID: 21437711.

37. Tietjen GE, Peterlin BL. Childhood abuse and migraine: epidemiology, sex differences, and potential mechanisms. Headache. 2011; 51:869–879. PMID: 21631473.

38. Toldo I, Perissinotto E, Menegazzo F, Boniver C, Sartori S, Salviati L, et al. Comorbidity between headache and epilepsy in a pediatric headache center. J Headache Pain. 2010; 11:235–240. PMID: 20112041.